The AP2M1 antibody is a crucial tool in studying the adaptor protein complex 2 mu subunit (AP2M1), a key component of the heterotetrameric AP-2 complex involved in clathrin-mediated endocytosis (CME). AP2M1 facilitates the internalization of transmembrane receptors, cargo proteins, and lipids by linking clathrin to vesicle membranes and recognizing specific sorting signals like tyrosine-based motifs. This antibody helps researchers detect AP2M1 expression levels, monitor its subcellular localization, and explore its role in membrane trafficking pathways.
Dysregulation of AP2M1 is associated with neurodevelopmental disorders, cancer progression, and neurological conditions such as Alzheimer’s disease, where impaired CME contributes to amyloid-beta pathology. Studies also link AP2M1 mutations to rare genetic diseases like MEDNIK syndrome and hereditary spastic paraplegia. By enabling immunoassays (e.g., Western blot, immunofluorescence), the antibody supports investigations into AP2M1’s interaction partners, post-translational modifications, and functional alterations in disease models. Its specificity and reliability make it essential for dissecting molecular mechanisms of endocytosis and developing therapeutic strategies targeting membrane trafficking defects.